Arbutus Biopharma Corporation ABUS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 81.7%+1,373pp | -271%+966pp | -320.4%+913pp | -386.5%+441pp | -1,290.9%-674pp | |
| Net margin | 84%+1,280pp | -237.9%+895pp | -289.4%+848pp | -351.9%+414pp | -1,195.9%-623pp | |
| Returns | ||||||
| Return on equity | 94.7%+174pp | -38.5%+30.2pp | -45.9%+21.9pp | -52.8%+7.1pp | -79%-21.5pp | |
| Return on invested capital | 111.6%+254pp | -62.7%+43.4pp | -70.7%+21.6pp | -110.4%-12.9pp | -141.9%-52.3pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.9× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 54.3×+48.3× | 15.7×+7.6× | 18.8×+11.8× | 20.5×+14.0× | 6×-0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.1×— | —— | —— | —— | —— | |
| Per Share | ||||||
| Book value per share | $1.33+221% | $0.40-23.8% | $0.40-28.6% | $0.43-33.8% | $0.42-36.4% | |
| Valuation | ||||||
| Market capitalization | $881.02M+34.1% | $925.08M+49.3% | $870.31M+19.7% | $645.45M+10.7% | $668.27M+44.3% | |
| Price / earnings | 5.5×— | —— | —— | —— | —— | |
| Price / sales | 4.6×-98.0× | 65.7×-34.7× | 59.6×-48.2× | 41.9×-16.1× | 104.4×+68.7× | |
| Price / book | 3.4×-4.9× | 12.1×+5.7× | 11.2×+4.4× | 7.8×+3.0× | 8.4×+4.4× | |
| EV / EBITDA | 5.5×— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arbutus Biopharma Corporation's ratios come from?
- Every ratio is computed from Arbutus Biopharma Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
